Broad cross-protection against H5N1 avian influenza virus infection by means of monoclonal antibodies that map to conserved viral epitopes

Journal of Infectious Diseases

Volumn 199, Issue 1, 2009, Pages 49-58

  Chen, Yixin ^a,d   Qin, Kun ^b   Wai, Lan Wu ^b   Li, Guoqiang ^a   Zhang, Jun ^a   Du, Hailian ^a   Mun, Hon Ng ^a   Shih, J Wai Kuo ^a   Peiris, J S Malik ^b   Guan, Yi ^b,c   Chen, Honglin ^b,c   Xia, Ningshao ^a  

^a XIAMEN UNIVERSITY   (China)

^b UNIVERSITY OF HONG KONG   (Hong Kong)

^c SHANTOU UNIVERSITY   (China)

^d THE UNIVERSITY OF HONG KONG   (Hong Kong)

Author keywords

[No Author keywords available]

Indexed keywords

CROSS REACTING ANTIBODY; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY 13D4; MUTANT PROTEIN; UNCLASSIFIED DRUG; VIRUS HEMAGGLUTININ;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIGEN BINDING; ANTIGENICITY; ARTICLE; CONTROLLED STUDY; DOSE RESPONSE; DRUG BINDING SITE; DRUG DOSE ESCALATION; DRUG MEGADOSE; EPITOPE MAPPING; FEMALE; INFLUENZA; INFLUENZA VIRUS A H5N1; LUNG PARENCHYMA; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN ANALYSIS; VIRUS NEUTRALIZATION; VIRUS STRAIN; WEIGHT CHANGE;

ANIMALS; ANTIBODIES, MONOCLONAL; BIRDS; BODY WEIGHT; CHICK EMBRYO; CONSERVED SEQUENCE; CROSS REACTIONS; EPITOPES; HEMAGGLUTINATION INHIBITION TESTS; HUMANS; INFLUENZA A VIRUS, H5N1 SUBTYPE; INFLUENZA IN BIRDS; INFLUENZA VACCINES; INFLUENZA, HUMAN; MICE; MICE, INBRED BALB C;

EID: 58749101350     PISSN: 00221899     EISSN: None     Source Type: Journal    
DOI: 10.1086/594374     Document Type: Article

References (41)

1. Abdel-Ghafar AN, Chotpitayasunondh T, Gao Z, et al. Update on avian influenza A (H5N1) virus infection in humans. N Engl J Med 2008; 358:261-73.
2. Schunemann HJ, Hill SR, Kakad M, et al. WHO Rapid Advice Guidelines for pharmacological management of sporadic human infection with avian influenza A (H5N1) virus. Lancet Infect Dis 2007; 7:21-31.
3. Cheung CL, Rayner JM, Smith GJ, et al. Distribution of amantadine-resistant H5N1 avian influenza variants in Asia. J Infect Dis 2006; 193:1626-9.
4. Leneva IA, Roberts N, Govorkova EA, Goloubeva OG, Webster RG. The neuraminidase inhibitor GS4104 (oseltamivir phosphate) is efficacious against A/Hong Kong/156/97 (H5N1) and A/Hong Kong/1074/99 (H9N2) influenza viruses. Antiviral Res 2000; 48:101-15.
5. Gubareva LV, Webster RG, Hayden FG. Comparison of the activities of zanamivir, oseltamivir, and RWJ-270201 against clinical isolates of influenza virus and neuraminidase inhibitor-resistant variants. Antimicrob Agents Chemother 2001; 45:3403-8.
6. Sugaya N, Mitamura K, Yamazaki M, et al. Lower clinical effectiveness of oseltamivir against influenza B contrasted with influenza A infection in children. Clin Infect Dis 2007; 44:197-202.
7. Marasco WA, Sui J. The growth and potential of human antiviral monoclonal antibody therapeutics. Nat Biotechnol 2007; 25:1421-34.
8. Luke TC, Kilbane EM, Jackson JL, Hoffman SL. Meta-analysis: convalescent blood products for Spanish influenza pneumonia: a future H5N1 treatment? Ann Intern Med 2006; 145:599-609.
9. Zhou B, Zhong N, Guan Y. Treatment with convalescent plasma for influenza A (H5N1) infection. N Engl J Med 2007; 357:1450-1.
10. Lu J, Guo Z, Pan X, et al. Passive immunotherapy for influenza A H5N1 virus infection with equine hyperimmune globulin F(ab′)2 in mice. Respir Res 2006; 7:43.
11. Simmons CP, Bernasconi NL, Suguitan AL, et al. Prophylactic and therapeutic efficacy of human monoclonal antibodies against H5N1 influenza. PLoS Med 2007; 4:e178.
12. Hanson BJ, Boon AC, Lim AP, Webb A, Ooi EE, Webby RJ. Passive immunoprophylaxis and therapy with humanized monoclonal antibody specific for influenza A H5 hemagglutinin in mice. Respir Res 2006; 7:126.
13. Chen H, Smith GJ, Li KS, et al. Establishment of multiple sublineages of H5N1 influenza virus in Asia: implications for pandemic control. Proc Natl Acad Sci U S A 2006; 103:2845-50.
14. Smith GJ, Fan XH, Wang J, et al. Emergence and predominance of an H5N1 influenza variant in China. Proc Natl Acad Sci U S A 2006; 103:16936-41.
15. Wu WL, Chen Y, Wang P, et al. Antigenic profile of avian H5N1 viruses in Asia from 2002-2007. J Virol 2008; 82:1798-807.
16. Chutinimitkul S, Songserm T, Amonsin A, et al. New strain of influenza A virus (H5N1), Thailand. Emerg Infect Dis 2007; 13:506-7.
17. Boltz DA, Douangngeun B, Sinthasak S, et al. H5N1 influenza viruses in Lao People's Democratic Republic. Emerg Infect Dis 2006; 12:1593-5.
18. Ducatez MF, Olinger CM, Owoade AA, et al. Avian flu: multiple introductions of H5N1 in Nigeria. Nature 2006; 442:37.
19. Wang G, Zhan D, Li L, et al. H5N1 avian influenza re-emergence of Lake Qinghai: phylogenetic and antigenic analyses of the newly isolated viruses and roles of migratory birds in virus circulation. J Gen Virol 2008; 89:697-702.
20. Lipatov AS, Evseenko VA, Yen HL, et al. Influenza (H5N1) viruses in poultry, Russian Federation, 2005-2006. Emerg Infect Dis 2007; 13:539-46.
21. Yingst SL, Saad MD, Felt SA. Qinghai-like H5N1 from domestic cats, northern Iraq. Emerg Infect Dis 2006; 12:1295-7.
22. Sedyaningsih ER, Isfandari S, Setiawaty V, et al. Epidemiology of cases of H5N1 virus infection in Indonesia, July 2005-June 2006. J Infect Dis 2007; 196:522-7.
23. Smith GJ, Naipospos TS, Nguyen TD, et al. Evolution and adaptation of H5N1 influenza virus in avian and human hosts in Indonesia and Vietnam. Virology 2006; 350:258-68.
24. Reed LJ, Muench H. A simple method for estimating fifty percent endpoints. Am J Hyg 1938; 27:3-497.
25. Vareckova E, Betakova T, Mucha V, et al. Preparation of monoclonal antibodies for the diagnosis of influenza A infection using different immunization protocols. J Immunol Methods 1995; 180:107-16.
26. World Health Organization. Online report: toward a unified nomenclature system for highly pathogenic avian influenza virus (H5N1). Emerg Infect Dis 2008; 14:e1.
27. World Health Organization (WHO). Manual on animal influenza diagnosis and surveillance. Geneva, Switzerland: WHO, 2002. Available at: http://www.who.int/csr/resources/publications/influenza/en/whocdscsrncs20025rev. pdf. Accessed 23 October 2008.
28. Kaverin NV, Rudneva IA, Ilyushina NA, et al. Structure of antigenic sites on the haemagglutinin molecule of H5 avian influenza virus and phenotypic variation of escape mutants. J Gen Virol 2002; 83:2497-505.
29. Rowe T, Abernathy RA, Hu-Primmer J, et al. Detection of antibody to avian influenza A (H5N1) virus in human serum by using a combination of serologic assays. J Clin Microbiol 1999; 37:937-43.
30. Webster RG, Laver WG. Determination of the number of nonoverlapping antigenic areas on Hong Kong (H3N2) influenza virus hemagglutinin with monoclonal antibodies and the selection of variants with potential epidemiological significance. Virology 1980; 104:139-48.
31. Guan Y, Peiris JS, Lipatov AS, et al. Emergence of multiple genotypes of H5N1 avian influenza viruses in Hong Kong SAR. Proc Natl Acad Sci U S A 2002; 99:8950-5.
32. Li KS, Guan Y, Wang J, et al. Genesis of a highly pathogenic and potentially pandemic H5N1 influenza virus in eastern Asia. Nature 2004; 430:209-13.
33. Xu X, Subbarao, Cox NJ, Guo Y. Genetic characterization of the pathogenic influenza A/Goose/Guangdong/1/96 (H5N1) virus: similarity of its hemagglutinin gene to those of H5N1 viruses from the 1997 outbreaks in Hong Kong. Virology 1999; 261:15-9.
34. Gu J, Xie Z, Gao Z, et al. H5N1 infection of the respiratory tract and beyond: a molecular pathology study. Lancet 2007; 370:1137-45.
35. Gao P, Watanabe S, Ito T, et al. Biological heterogeneity, including systemic replication in mice, of H5N1 influenza A virus isolates from humans in Hong Kong. J Virol 1999; 73:3184-9.
36. Kaverin NV, Rudneva IA, Govorkova EA, et al. Epitope mapping of the hemagglutinin molecule of a highly pathogenic H5N1 influenza virus by using monoclonal antibodies. J Virol 2007; 81:12911-7.
37. Webster RG, Peiris M, Chen H, Guan Y. H5N1 outbreaks and enzootic influenza. Emerg Infect Dis 2006; 12:3-8.
38. World Health Organization. Pandemic flu protocol. 2006. Available at: http://www.who.int/csr/disease/avian-influenza/guidelines/ pandemicfluprotocol-17.03a.pdf. Accessed 23 October 2008.
39. Philpott M, Easterday BC, Hinshaw VS. Neutralizing epitopes of the H5 hemagglutinin from a virulent avian influenza virus and their relationship to pathogenicity. J Virol 1989; 63:3453-8.
40. Philpott M, Hioe C, Sheerar M, Hinshaw VS. Hemagglutinin mutations related to attenuation and altered cell tropism of a virulent avian influenza A virus. J Virol 1990; 64:2941-7.
41. Yamada S, Suzuki Y, Suzuki T, et al. Haemagglutinin mutations responsible for the binding of H5N1 influenza A viruses to human-type receptors. Nature 2006; 444:378-82.